New Delhi, Jul 16 (PTI) Biocon Biologics on Wednesday said it has received approval from the US health regulator to market a diabetes treatment medication.

The company, a unit of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for Kirsty as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).

Also Read | Kolkata Fatafat Result Today, July 16, 2025: Kolkata FF Live Winning Numbers Released, Know When and Where To Check Result Chart of Satta Matka-Type Lottery Game.

Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

The medication will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use, Biocon said in a statement.

Also Read | Aadhaar Free Update: Government Requests Parents to Update Children's Aadhaar Biometrics Between Age 5-7, Free of Cost.

The approval expands Biocon Biologics' biosimilar insulin portfolio, which also includes the interchangeable biosimilar, Semglee (Insulin Glargine-yfgn Injection).

An interchangeable product (IP) is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product (RP).

Kirsty has been available in Europe and Canada since 2022.

As per the company, there are 38.4 million people with diabetes in the US, around 11.6 per cent of the total population, with nearly a quarter of them being undiagnosed.

An additional 97.6 million Americans have been identified as prediabetic, it added.

According to IQVIA, sales of Insulin Aspart in the US stood around USD 1.9 billion in 2024.

Shares of Biocon were trading 1.44 per cent up at Rs 395.80 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)